Focus Moves to Earlier Settings in Melanoma

Gina Battaglia, PhD
Published: Monday, Feb 12, 2018
Dr Axel Hauschild, MD
Axel Hauschild, MD
Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy. Optimizing systemic therapy to maximize efficiency and minimize adverse events (AEs) will be the next step moving forward, according to panelists who participated in an OncLive Peer Exchange® panel.

The trend in melanoma therapy has been toward combinations, and Hauschild said he expects that to continue. Sequencing drugs correctly will be important, he noted.

Role of Surgery in Locoregional Disease

Neoadjuvant Therapy
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication